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Abstract This review evaluates the hypothesis that the
cardiac effects of amiodarone can be explained—at least
partly—by the induction of a local ‘hypothyroid-like con-
dition’ in the heart. Evidence supporting the hypothesis
comprises the observation that amiodarone exerts an
inhibitory effect on the binding of T3 to thyroid hormone
receptors (TR) alpha-1 and beta-1 in vitro, and on the
expression of particular T3-dependent genes in vivo. In the
heart, amiodarone decreases heart rate and alpha myosin
heavy chain expression (mediated via TR alpha-1), and
increases sarcoplasmic reticulum calcium-activated ATP-
ase and beta myosin heavy chain expression (mediated via
TR beta-1). Recent data show a signiﬁcant similarity in
expression proﬁles of 8,435 genes in the heart of hypo-
thyroid and amiodarone-treated animals, although
similarities do not always exist in transcripts of ion channel
genes. Induction of a hypothyroid cardiac phenotype by
amiodarone may be advantageous by decreasing energy
demands and increasing energy availability.
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Introduction
The heart is an important target organ for thyroid hormone
as evident from clinical practice [1]. In hyperthyroid
patients there is an increased resting heart rate, increased
left ventricular contractility, increased cardiac output and a
decreased systemic vascular resistance, resulting in a lower
diastolic and higher systolic blood pressure; serum cho-
lesterol is decreased and patients are susceptible to cardiac
arrhythmias, speciﬁcally to atrial ﬁbrilation. In contrast,
hypothyroid patients have a decreased heart rate, impaired
cardiac contractility and diastolic function, decreased car-
diac output and an increased systemic vascular resistance,
resulting in a higher diastolic blood pressure; serum cho-
lesterol is increased and patients are susceptible to
accelerated atherosclerosis and coronary artery disease.
The aberrant cardiovascular functions in hyperthyroid and
hypothyroid patients are usually fully reversible upon res-
toration of the euthyroid state.
Amiodarone, introduced originally as an anti-anginal
agentbutnowadaysusedasaverypotentantiarrhytmicdrug,
lowers heart rate, lengthens the cardiac action potential
(manifest as a longer QTc interval on the EKG), and
depresses myocardial oxygen consumption [2]. In addition,
amiodarone increases plasma cholesterol [3]. Similarities
between the effects of amiodarone and of hypothyroidism
are striking. It has therefore been hypothesized that the car-
diac effects of amiodarone can be explained—at least
partly—by the induction of a local ‘hypothyroid-like’ con-
dition in the heart [3]. In this review we present evidence in
favour of this hypothesis derived from experimental animal
studies focussing on nuclear T3 receptors and thyroid hor-
mone-dependent gene expression in the heart.
Hypothyroidism
Genomic effects of thyroid hormone in the heart are medi-
ated via nuclear T3 receptors (TR). There are several
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ligand T3) and TRa2 (which does not bind T3 but is able to
bind to thyroid response elements (TRE) and may exert a
dominant negative effect on gene expression). The heart is a
predominantlyTRa1organ,althoughTRb1isalsoexpressed
albeit at a lower level. In rats made hypothyroid by adding
0.05% propylthiouracil to their drinking water for 2 weeks,
we did not observe any changes in atrial or ventricular gene
expressionofthethreeTRsrelativetocontrols,neitheratthe
mRNA level nor at the protein level [4]. Other models,
however, did show changes in the expression of particular
TR isoforms in hypothyroid rats [5, 6]. The discrepancy can
be explained by the more severe hypothyroidism in these
earlier studies by using propylthiouracil for a longer period
of time (six instead of our 2 weeks) or combining propyl-
thiouracilwithalowiodinediet[5,6].Becauseinourmodel
cardiac TR levels are not affected by thyroid hormone deﬁ-
ciency, observed changes in the expression of T3-dependent
genes in the hypothyroid heart are likely attributed to a low
occupancy rate of TR with T3.
There are a number of T3-responsive genes in the heart
encoding for proteins involved in cardiac contractility.
Examples are the sarcoplasmic reticulum calcium-activated
ATPase (SERCA2a) which is responsible for the calcium
reuptake during the diastole and is activated by T3 [7], and
the two myosin heavy chains a and b (aMHC and bMHC,
respectively) which are myoﬁbrillar proteins that make up
the thick ﬁlament of the cardiac myocyte contractile
apparatus. In rodents, transcription of aMHC is activated
by T3, whereas transcription of bMHC is repressed by T3
[8, 9]. In our experimental model, hypothyroidism was
associated with a downregulation of aMHC and an
upregulation of bMHC (both at the mRNA and at the
protein level) in atria and ventricles; SERCA2a was sig-
niﬁcantly downregulated in atria and ventricles [4]. The
observed changes are in good agreement with previous
reports in the literature [8–10]. Downregulation of aMHC
(the fast myosin with higher ATPase activity) under
simultaneous upregulation of bMHC (the slow myosin),
together with the downregulation of SERCA2a explains to
a certain extent the decreased cardiac contractility associ-
ated with hypothyroidism [1]. Modulation of aMHC
transcription is linked to the TRa1 isoform, whereas tran-
scription of bMHC and SERCA2a genes seems to be under
control of TRb1[ 11].
Amiodarone
Amiodarone treatment (100 mg/kg/day orally for 2 weeks)
inﬂuences cardiac TR mRNA expression [12]: TRa1i s
decreased in the right atrium but increased in the left
ventricular wall, TRa2 remains unchanged at these
locations, and TRb1 is decreased both in the right atrium
and the left ventricular wall. The overall downregulation of
TR by amiodarone is similar to the reported downregula-
tion of TRa1 and TRb1 in the post-infarcted rat heart,
which shows a hypothyroid cardiac phenotype [13].
Amiodarone treatment also inﬂuenced thyroid hormone-
dependent gene expression in our experimental rat model at
the mRNA level [12]: SERCA2a was reduced in the right
atrium, aMHC was reduced both in the right atrium and left
ventricular apex, whereas bMHC was increased in the right
atrium, left ventricular wall and apex. The ﬁndings are in
good agreement with the literature [14].
The data strongly suggests that amiodarone induces a
hypothyroid-like phenotype with regard to T3-dependent
gene expression in the heart. To learn about the mechanism
by which amiodarone exerts these effects, we performed a
number of in vitro and in vivo studies. First, in vitro
experiments demonstrated that amiodarone via its main
metabolite desethylamiodarone (DEA) acts as a competitive
inhibitor of T3 binding to TRa1 (IC50 value 30 ± 3.9 lM)
and as a noncompetitive inhibitor of T3 binding to TRb1
(IC50 value 71 ± 3.4 lM)[15, 16]. Next to inhibition of T3
binding to TR, DEA may further affect T3-dependent gene
expression by inhibition of co-activator binding to TR and
inhibition of the TR binding to TRE [17, 18]. Second, DEA
concentrations in the rat heart after amiodarone treatment
(100 mg/kg/day orally for 2 weeks) are in the micromolar
range (14 lmol/kg) [19], close to the IC50 values of DEA
for inhibiting T3 binding to TR in vitro. The T3 concen-
trations in rat heart are 4 times lower in amiodarone-treated
animals than in control animals (1 vs 4 nmol/kg, respec-
tively) [20]. The marked decrease in myocardial T3
concentration is related to the decrease of plasma T3 and the
impaired entrance of plasma-derived T3 in hearts of ami-
odarone-treated animals [21]. The reduction of cardiac TR
and T3 concentrations will result in all likelihood in a low
occupancy of TR with T3, which favours the inhibitory
effects of DEA [15, 16]. The ﬁnding that amiodarone
modulates the gene expression of both aMHC (mediated via
TRa1) and bMHC and SERCA2a (mediated via TRb1) is in
line with the inhibitory effect of DEA on the binding of T3
to both TRa1 and TRb1.
Dronedarone
Dronedarone is a newly developed antiarrhythmic drug,
structurally related to amiodarone. It lacks, however, the
iodine moiety of amiodarone, and thereby iodine-related
toxicity. Dronedarone like amiodarone has antiadrenergic
effects as well as blocking effects on many ion channels.
Dronedarone possesses rate-control and rhythm-control
properties, and seems to be safe and effective in preventing
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123recurrence of atrial ﬁbrillation [22]. We wondered if part of
the pharmacological actions of dronedarone could also be
attributed to induction of a local hypothyroid-like condition
in the heart.
In vitro experiments demonstrate that debutyldroneda-
rone (the major metabolite of dronedarone) inhibits the
binding of T3 to TRa1 (IC50 value 59 ± 4.1 lM) much
more strongly than the binding of T3 to TRb1 (IC50 value
280 ± 29 lM) [23]. Inhibition of T3 binding to TRa1b y
debutyldronedarone is competitive in nature. Treating rats
with dronedarone (100 mg/kg/day orally for 2 weeks)
decreases TRa1 mRNA in the right atrium, decreases TRb1
mRNA in right atrium, left ventricular wall and apex,
whereas it does not affect TRa2 mRNA in the heart [12].
With regard to T3-dependent gene expression, dronedarone
did not change aMHC, bMHC and SERCA2a expression in
the heart [12]. Pantos et al. [24] also did not observe a
change in bMHC or SERCA2a cardiac expression in rats
treated with dronedarone (90 mg/kg/d orally for 2 weeks),
but did ﬁnd a signiﬁcant decrease in aMHC and heart rate.
These ﬁndings are most interesting: the presence of an
effect of dronedarone on heart rate and aMHC (both TRa1
mediated) and the absence of an effect of dronedarone on
bMHC and SERCA2a (both TRb1 mediated) reinforce the
in vitro ﬁndings that dronedarone acts as a selective TRa1
antagonist. This has also been demonstrated in another rat
study in which treatment with amiodarone reduced the
expression of two TRb1-dependent genes (as evident from a
lower LDL receptor protein concentration and a lower iodo-
thyronine-50-deiodinase-activity in liver), whereas treatment
with dronedarone did not [23].
Whether dronedarone like amiodarone also induces a
local hypothyroid-like condition in the heart is less clear.
However, further biochemical and functional studies
showed many similarities in hearts of hypothyroid and
dronedarone-treated rats, leading these authors to conclude
that dronedarone treatment results in cardioprotection by
selectively mimicking hypothyroidism [24].
Hypothyroid cardiac phenotype
Amiodarone treatment, like hypothyroidism, lowers heart
rate, lenghthens the QTc interval, and lowers aMHC gene
expression in the heart; these effects are TRa1-mediated
effects. Amiodarone treatment, like hypothyroidism,
increases bMHC and decreases SERCA2a gene expression
in the heart; both effects are TRb1-mediated effects. The
data provides supportive evidence for the hypothesis that
amiodarone induces a hypothyroid-like condition in the
heart. Amiodarone apparently switches gene expression
back into foetal programming of particular cardiac genes,
which might have survival value for the organism.
Thehypothesisisfurtherstrengthenedbyrecentdatafrom
a microarray analysis of 8,435 genes in the left ventricular
myocardium of rats [25]. There was a very signiﬁcant sim-
ilarity in expression proﬁles between hypothyroid and
amiodarone-treated rats (R = 0.63, P\0.00001); the cor-
relationbecameevenstrongerwhenthetop100up-regulated
and 100 down-regulated genes in hypothyroidism were
analyzed (R = 0.78, P\0.00001).
As a ﬁnal remark, however, it should be mentioned that
not all pharmacological actions of amiodarone can be
explained from the induction of a local hypothyroid-like
condition in the heart. Evaluating the complete ion channel
repertoire by real time PCR in hearts of mice treated with
amiodarone, it became obvious that changes in transcript
levels sometimes were similar to those seen in hypothyroid
mice, but very frequently were completely different from
the hypothyroid phenotype [26, 27]. Nevertheless, down-
regulation of the effect of thyroid hormone in the heart
results in what has been called ‘‘cardiac metamorphosis’’
[28], which by decreasing energy demands and increasing
energy availability might be advantageous with potential
therapeutic implications.
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